25,654 Shares in Globus Medical, Inc. $GMED Purchased by Hsbc Holdings PLC

Hsbc Holdings PLC acquired a new stake in shares of Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,654 shares of the medical device company’s stock, valued at approximately $2,254,000.

A number of other large investors also recently bought and sold shares of the company. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the 3rd quarter worth approximately $26,000. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in Globus Medical by 98.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the last quarter. Finally, Headlands Technologies LLC boosted its position in Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after acquiring an additional 631 shares during the period. Institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

Globus Medical Stock Down 3.0%

Shares of NYSE GMED opened at $83.68 on Tuesday. The stock’s fifty day simple moving average is $83.39 and its 200 day simple moving average is $87.37. The stock has a market capitalization of $11.36 billion, a price-to-earnings ratio of 19.46, a PEG ratio of 1.78 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last announced its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. During the same period in the prior year, the business posted $0.68 earnings per share. Globus Medical’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Analyst Ratings Changes

GMED has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Needham & Company LLC boosted their price objective on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Royal Bank Of Canada upped their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Piper Sandler decreased their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and an average target price of $105.00.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.